As of close of business last night, Silk Road Medical Inc’s stock clocked out at $18.97, up 2.99% from its previous closing price of $18.42. In other words, the price has increased by $+0.55 from its previous closing price. On the day, 843732 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of SILK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.97 and its Current Ratio is at 7.95. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.55.
On January 19, 2024, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $9 to $20.
On January 03, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $20.Lake Street initiated its Buy rating on January 03, 2024, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Ballinger Kevin J. bought 11,700 shares for $16.99 per share. The transaction valued at 198,783 led to the insider holds 17,807 shares of the business.
Buchanan Lucas W. sold 9,877 shares of SILK for $169,578 on Mar 05 ’24. The COO/CFO now owns 500,925 shares after completing the transaction at $17.17 per share. On Mar 05 ’24, another insider, Davis Andrew S., who serves as the Chief Commercial Officer of the company, sold 5,481 shares for $17.17 each. As a result, the insider received 94,103 and left with 287,773 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SILK now has a Market Capitalization of 742.36M and an Enterprise Value of 638.21M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.19 while its Price-to-Book (P/B) ratio in mrq is 4.92. Its current Enterprise Value per Revenue stands at 3.60 whereas that against EBITDA is -14.16.
Stock Price History:
Over the past 52 weeks, SILK has reached a high of $46.57, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is 15.94, while the 200-Day Moving Average is calculated to be 16.86.
Shares Statistics:
It appears that SILK traded 881.45K shares on average per day over the past three months and 902.92k shares per day over the past ten days. A total of 39.17M shares are outstanding, with a floating share count of 36.54M. Insiders hold about 6.71% of the company’s shares, while institutions hold 104.62% stake in the company. Shares short for SILK as of Feb 29, 2024 were 4.32M with a Short Ratio of 4.90, compared to 3.59M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.03% and a Short% of Float of 11.24%.
Earnings Estimates
As of right now, 8 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.42, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.32 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.32 and -$1.5 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is -$1.3, with 10 analysts recommending between -$1.17 and -$1.57.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $44.68M. It ranges from a high estimate of $45M to a low estimate of $43.8M. As of the current estimate, Silk Road Medical Inc’s year-ago sales were $40.69M, an estimated increase of 9.80% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $49.07M, an increase of 8.30% less than the figure of $9.80% in the same quarter last year. There is a high estimate of $50.1M for the next quarter, whereas the lowest estimate is $47.6M.
A total of 9 analysts have provided revenue estimates for SILK’s current fiscal year. The highest revenue estimate was $196.7M, while the lowest revenue estimate was $194M, resulting in an average revenue estimate of $195.92M. In the same quarter a year ago, actual revenue was $177.13M, up 10.60% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $217.79M in the next fiscal year. The high estimate is $225.41M and the low estimate is $213M. The average revenue growth estimate for next year is up 11.20% from the average revenue estimate for this year.
